Nuvectis Pharma (NVCT) Corporate presentation summary

Management and strategic partnerships

• Leadership team has a track record of securing global regulatory approvals in renal, anemia, and oncology indications.

• Entered a transformative licensing agreement with Haisco Pharmaceutical Group, a partner with extensive marketed products and research programs.

• Haisco has a history of successful licensing deals and drug development, including positive Phase 3 data for a TYK2 inhibitor.

Financial highlights and capital position

• Completed a $115M follow-on offering in July 2026.

• Cash runway extends into the first half of 2029, supporting broad clinical plans.

• Positioned to reach key inflection points with multiple near-term clinical and regulatory catalysts expected.

Pipeline overview and clinical progress

• Ciprocopan (NXP100): Once-daily, oral Factor B inhibitor for complement-related diseases, approved in China for treatment-naïve PNH, with additional indications in late-stage studies.

• NXP200: Oral, brain-penetrant, paradox-breaker BRAF inhibitor in Phase 1b for solid tumors and CNS cancers, showing durable single-agent responses.

• NXP900: SRC/YES1 kinase inhibitor in Phase 1b combination studies for NSCLC and planned studies in pancreatic cancer.